2 results
Approved WMOCompleted
To assess the effect of switching CML patients, who have been treated with imatinib *2 years and who have stable detectable molecular residual disease above 0.01% (IS), to the combination of Nilotinib and PegIFN, in terms of the proportion of…
Approved WMOCompleted
Primary Objectives:- To determine the clinical efficacy of IRE ablation of small renal masses (* 4cm), assessed by calculating recurrence and residual disease at follow-up, measured through the (non-)presence of tumour enhancement on cross-sectional…